Latest Breaking News On - Obecabtagene autoleucel - Page 1 : comparemela.com

Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancersSEATTLE, May 31, 2024 Adaptive.

Adaptive Biotechnologies Announces Data Supporting the

Obecabtagene Autoleucel BLA for Relapsed/Refractory B-ALL Under FDA Review

The FDA has accepted for review the BLA for obecabtagene autoleucel's use in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Obecabtagene Autoleucel (obe-cel, AUTO1) for Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Pooled Analysis of the Ongoing FELIX Phase Ib/II Study

Claire Roddie, MD, PhD, presents data from the pooled analysis of the ongoing FELIX phase Ib/II study investigating obecabtagene autoleucel in patients with relapsed/refractory adult B-cell acute lymphoblastic leukemia.

Autolus Therapeutics (AUTL) Presents Clinical Data Updates